ENSC Stock — Ensysce Biosciences Inc.: Cash, EV, Pipeline

Share price

$0.46

Market cap

$8.9M

Cash

$0.7M

Enterprise value

$8.2M

Balance sheet

Cash	$0.7M
Debt	$0.0M
Net cash	$0.7M
Enterprise value	$8.2M
Basic shares	16.2M shares
Fully diluted shares	37.3M shares
Fully diluted market cap	$17.2M
Cash per share	$0.04

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ENSC daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Oct 24, 2026	PF614 capsule	Phase 3	Postoperative Pain, Acute	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PF614

Phase 3 · Active Modality: small molecule prodrug (TAAP opioid)

Partnerships Product development and manufacturing collaboration with Galephar (milestone consideration modified Jul 1, 2026 to 2,171 Series C Preferred shares).

Indications

Chronic pain (Phase 3)

Status note Extended-release TAAP (Trypsin Activated Abuse Protection) prodrug of oxycodone; designed to resist abuse, overdose and misuse, with MPAR (Multi-Pill Abuse Resistance) technology for overdose protection to be applied to the PF614 program. Timing of the Phase 3 trial depends on raising sufficient capital.

PF614-MPAR

Phase 1 · Active Modality: drug delivery technology (TAAP + MPAR)

Indications

Chronic pain (overdose protection layer on TAAP opioids) (Phase 1)
Opioid use disorder (methadone prodrug) (Preclinical)

Status note Phase 1b clinical development. MPAR adds a layer of overdose protection to each TAAP product. TAAP and MPAR technology also being applied to a methadone prodrug for opioid use disorder. Federal MPAR grant funding ($5.3M remaining at Jun 30, 2026, expected to be utilized by May 2027).

Nafamostat

Phase 1 · Active Modality: small molecule

Target Trypsin

Indications

Chronic pain (Phase 1)

Status note Completed Phase 1 clinical development; among the lead product candidates being tested for chronic pain.

Cy Biopharma lead candidate (unnamed in filing)

Stage not disclosed · Active

Partnerships Acquired via Cy Biopharma, Inc. merger completed Aug 5, 2026 (Series C Preferred Stock consideration; concurrent $21.5M private placement with up to ~$38.6M additional milestone tranche).

Indications

Complex Regional Pain Syndrome (CRPS) Type 1 (Stage not disclosed)

Status note Cy Biopharma is a clinical-stage biotech focused on chronic pain therapies; its lead candidate for CRPS Type 1 has received FDA Orphan Drug Designation. Candidate name, modality and trial phase not disclosed in the excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PF614 capsule
Lead indication	Postoperative Pain, Acute
Lead phase	Phase 3
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06602271	Phase 3	Recruiting	Sponsor	ENSC	—	Postoperative Pain, Acute	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Ensysce Biosciences on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ENSC — Ensysce Biosciences Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials